-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate
We're Not Very Worried About MicroPort CardioFlow Medtech's (HKG:2160) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. Having said that, unprofitable companies are risky because they could potentially burn through all their cash and become distressed.
So should MicroPort CardioFlow Medtech (HKG:2160) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway.
Check out our latest analysis for MicroPort CardioFlow Medtech
Does MicroPort CardioFlow Medtech Have A Long Cash Runway?
A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. When MicroPort CardioFlow Medtech last reported its balance sheet in December 2021, it had zero debt and cash worth CN¥2.2b. Looking at the last year, the company burnt through CN¥270m. Therefore, from December 2021 it had 8.2 years of cash runway. Notably, however, analysts think that MicroPort CardioFlow Medtech will break even (at a free cash flow level) before then. In that case, it may never reach the end of its cash runway. Depicted below, you can see how its cash holdings have changed over time.
SEHK:2160 Debt to Equity History August 1st 2022How Well Is MicroPort CardioFlow Medtech Growing?
MicroPort CardioFlow Medtech actually ramped up its cash burn by a whopping 61% in the last year, which shows it is boosting investment in the business. While that certainly gives us pause for thought, we take a lot of comfort in the strong annual revenue growth of 93%. Considering the factors above, the company doesn't fare badly when it comes to assessing how it is changing over time. While the past is always worth studying, it is the future that matters most of all. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company.
How Easily Can MicroPort CardioFlow Medtech Raise Cash?
While MicroPort CardioFlow Medtech seems to be in a decent position, we reckon it is still worth thinking about how easily it could raise more cash, if that proved desirable. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. By comparing a company's annual cash burn to its total market capitalisation, we can estimate roughly how many shares it would have to issue in order to run the company for another year (at the same burn rate).
MicroPort CardioFlow Medtech's cash burn of CN¥270m is about 5.4% of its CN¥5.0b market capitalisation. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money.
How Risky Is MicroPort CardioFlow Medtech's Cash Burn Situation?
It may already be apparent to you that we're relatively comfortable with the way MicroPort CardioFlow Medtech is burning through its cash. In particular, we think its revenue growth stands out as evidence that the company is well on top of its spending. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. One real positive is that analysts are forecasting that the company will reach breakeven. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. Its important for readers to be cognizant of the risks that can affect the company's operations, and we've picked out 2 warning signs for MicroPort CardioFlow Medtech that investors should know when investing in the stock.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
即使一家企業在虧損,如果股東以合適的價格收購一家好企業,他們也有可能賺錢。例如,雖然亞馬遜上市後多年虧損,但如果你從1999年開始買入並持有股票,你就會發大財。話雖如此,沒有盈利的公司是有風險的,因為它們可能會燒掉所有的現金,陷入困境。
所以也應該這樣微港心流醫療技術公司(HKG:2160)股東擔心其燒錢嗎?就本文而言,我們將現金消耗定義為公司每年為其增長提供資金的現金數量(也稱為負自由現金流)。我們將首先將其現金消耗與其現金儲備進行比較,以計算其現金跑道。
查看我們對MicroPort HearoFlow Medtech的最新分析
Microport MedicoFlow Medtech有很長的現金跑道嗎?
現金跑道的定義是,如果一家公司繼續以目前的現金消耗速度支出,它需要多長時間才能耗盡資金。Microport HearoFlow Medtech上一次報告資產負債表是在2021年12月,當時它沒有債務和現金,價值22億元人民幣。回顧去年,該公司燒掉了2.7億元人民幣。因此,從2021年12月開始,它有了8.2年的現金跑道。然而,值得注意的是,分析人士認為,在此之前,Microport MedicoFlow Medtech將(在自由現金流水平上)實現盈虧平衡。在這種情況下,它可能永遠不會走到現金跑道的盡頭。如下所示,你可以看到它的現金持有量是如何隨着時間的推移而變化的。
聯交所:2160債轉股歷史2022年8月1日MicroPort MedicoFlow醫療技術公司的發展情況如何?
MicroPort MedicoFlow Medtech去年的現金消耗實際上增加了61%,這表明它正在增加對這項業務的投資。雖然這肯定會讓我們停下來思考,但我們對93%的強勁年收入增長感到非常欣慰。考慮到上述因素,在評估公司如何隨着時間的推移而發生變化時,該公司的表現並不差。雖然過去總是值得研究的,但最重要的是未來。因此,看看我們的分析師對該公司的預測是很有意義的。
Microport MedicoFlow Medtech籌集現金的難度有多大?
雖然MicroPort MedicoFlow Medtech似乎處於一個不錯的位置,但我們認為,如果事實證明這是可取的,它仍然值得考慮它可以多麼容易地籌集更多現金。一般來説,上市企業可以通過發行股票或承擔債務來籌集新的現金。許多公司最終發行新股,為未來的增長提供資金。通過將一家公司的年度現金消耗與其總市值進行比較,我們可以粗略地估計出它需要發行多少股票才能維持公司下一年的運營(以相同的消耗速度)。
微港心流醫療的現金消耗為2.7億元人民幣,約佔其50億元人民幣市值的5.4%。這是一個很低的比例,所以我們認為該公司將能夠籌集更多的現金來支持增長,只需一點點稀釋,甚至只是借一些錢。
Microport HearoFlow Medtech的現金燒燬情況有多大風險?
你可能已經很清楚了,我們對MicroPort MedicoFlow Medtech燒錢的方式相對滿意。特別是,我們認為它的收入增長突出,證明該公司很好地控制了支出。雖然它不斷增加的現金消耗並不是很好,但本文提到的其他因素足以彌補這一指標的疲軟。一個真正的積極因素是,分析師們預測,該公司將實現盈虧平衡。看看本文中的所有衡量標準,我們並不擔心它的現金消耗率;該公司似乎很好地滿足了中期支出需求。重要的是讓讀者認識到可能影響公司運營的風險,我們已經挑選出微港心流醫療科技公司的2個警告標誌投資者在投資股票時應該知道這一點。
當然了,如果你把目光投向別處,你可能會發現這是一筆很棒的投資。所以讓我們來看看這個免費感興趣的公司名單,以及這份名單中的成長股(根據分析師預測)
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧